Pembrolizumab in Combination With Low-dose PFas Neoadjuvant Treatment for Locally Advanced HNSCC
Status:
Not yet recruiting
Trial end date:
2025-08-01
Target enrollment:
Participant gender:
Summary
A phase Ⅱ open label multi-cencter clinical trail to evaluate the efficacy and safety of
pembrolizumab combined with low-dose PF (cisplatin + 5-fluorouracil) in the neoadjuvant
treatment of locally advanced head and neck squamous cell carcinoma